Related references
Note: Only part of the references are listed.Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
Stephen B. Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2020)
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Vince B. C. Biemans et al.
JOURNAL OF CROHNS & COLITIS (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
Davide Giuseppe Ribaldone et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
M. Iborra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE)
Anja Eberl et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Ustekinumab: Real-world outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease
Peter Hoffmann et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria
Sadik Saman et al.
INTESTINAL RESEARCH (2019)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis
Matthew J. Lee et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
Paul Rutgeerts et al.
GASTROENTEROLOGY (2018)
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
S. Tadbiri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
Grainne Holleran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy
Parakkal Deepak et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Ustekinumab in Crohn's disease: evidence to date and place in therapy
Tal Engel et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Share Paper
